Analysts Offer Predictions for electroCore FY2030 Earnings

electroCore, Inc. (NASDAQ:ECOR) – Equities researchers at HC Wainwright lifted their FY2030 earnings per share estimates for shares of electroCore in a research note issued to investors on Friday, March 20th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $1.01 for the year, up from their previous estimate of $0.90. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share.

electroCore (NASDAQ:ECOR) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.01. The firm had revenue of $9.24 million during the quarter, compared to the consensus estimate of $9.09 million. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 43.60%.

ECOR has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of electroCore in a report on Monday, December 29th. Zacks Research downgraded shares of electroCore from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 28th. Finally, raised shares of electroCore to a “strong-buy” rating in a research report on Tuesday, February 3rd. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $18.00.

electroCore Price Performance

NASDAQ ECOR opened at $6.25 on Monday. The firm has a market capitalization of $50.50 million, a P/E ratio of -3.79 and a beta of 0.48. electroCore has a 1-year low of $4.16 and a 1-year high of $8.64. The business’s 50-day simple moving average is $6.62 and its 200-day simple moving average is $5.56.

Hedge Funds Weigh In On electroCore

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC boosted its holdings in electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock worth $1,083,000 after acquiring an additional 145,047 shares during the period. Tejara Capital Ltd purchased a new stake in shares of electroCore during the fourth quarter valued at approximately $450,000. DRW Securities LLC purchased a new stake in shares of electroCore during the fourth quarter valued at approximately $264,000. Cubist Systematic Strategies LLC purchased a new stake in shares of electroCore during the first quarter valued at approximately $153,000. Finally, Jane Street Group LLC lifted its position in shares of electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after purchasing an additional 19,599 shares in the last quarter. 26.74% of the stock is owned by institutional investors and hedge funds.

More electroCore News

Here are the key news stories impacting electroCore this week:

• Positive Sentiment: Record full‑year sales: electroCore reported FY2025 net sales of $32.0M, up ~27% year‑over‑year driven by 25% growth in U.S. prescriptions and a 97% increase in general‑wellness sales. electroCore Announces Full Year 2025 Financial Results and Organizational Changes
• Positive Sentiment: Quarterly beat: Q4 EPS was a loss of $0.34, narrowly beating consensus by $0.01, and revenue of $9.24M modestly exceeded expectations — a sign of sales momentum despite ongoing losses. Q4 results / transcript
• Positive Sentiment: Growth outlook: management outlined the potential for ~30% revenue growth in 2026 as the leadership transition progresses, which, if realized, would re-rate investor expectations. ElectroCore outlines 30% revenue growth potential
• Neutral Sentiment: Organizational and leadership changes: the company announced structural changes and a leadership transition intended to support growth; the near‑term impact is unclear and will depend on execution. Press coverage of organizational changes
• Neutral Sentiment: Full Q4 earnings call transcript is available for details on commercialization progress, reimbursement trends and 2026 priorities — useful for investors who want management commentary on execution risks. Q4 2025 earnings call transcript
• Negative Sentiment: Profitability and metrics remain weak: electroCore is still loss‑making with a negative net margin (~47%) and extreme negative ROE (~‑448%); analysts still model a materially negative FY EPS (consensus ~‑1.49). These fundamentals leave the stock sensitive to execution misses. Company trading & fundamentals
• Negative Sentiment: Market reaction: shares have moved down on the news and trading volume has spiked vs. average, indicating investor re‑pricing while the company transitions management and pursues its growth plan. Market trading summary

About electroCore

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.